Navigation Links
Temprian Therapeutics Finalist in Nature Merck Spinoff 2020 Competition
Date:7/2/2020

Temprian, a spinoff from Northwestern University, has a platform technology intended for the treatment of autoimmune diseases. Its lead indication is vitiligo. Vitiligo patients develop progressive depigmentation of the skin. There is no cure for vitiligo at this time.

While vitiligo is equally prevalent in all ethnic groups, it is most visible and impactful in people with darker skin tones. Comorbidities include alopecia areata, hypothyroid disease and depression. The disease can bring heavy emotional stress. Patients are routinely subject to discrimination and prejudice, affecting personal relationships and job opportunities.

Historically, treatments for diseases that disproportionately affect people of color have received little attention or resources essential to moving them forward. Temprian’s selection as a finalist for the Nature Spinoff Prize provides hope for securing finances needed for a clinical trial.

The 12 finalists represent companies from the United States, United Kingdom, Switzerland and Spain operating in such diverse fields as pharmaceuticals, predictive assays and medical devices.

Details of Temprian’s innovation are covered on the Nature website. The Spinoff Prize has been established by the journal Nature in partnership with Merck KGaA to showcase and celebrate global excellence in the commercialization of research through the creation of spinoff companies.

ABOUT Temprian Therapeutics Inc. The company is a spinoff from Northwestern University, established to develop DNA based treatments for autoimmune disease. Its lead indication is vitiligo. The Company has worked closely with the patient community in the development of a safe, non-invasive, market-oriented treatment for vitiligo. The HSP70-based drug is designed to temper autoimmunity, arrests the spread of the disease and trigger repigmentation.

ABOUT Nature, Merck KGaA and the Spinoff Prize 2020: The Spinoff Prize has been established by the journal Nature Research in partnership with Merck to showcase and celebrate global excellence in the commercialization of research through the creation of spinoff companies.

IP: The underlying patent "Mutant HSP70i to Prevent Autoimmune Disease" (Appl. No. 15/791,609) for Temprian’s platform technology was approved and issued by the USPTO on May 27, 2020.

Read the full story at https://www.prweb.com/releases/temprian_therapeutics_finalist_in_nature_merck_spinoff_2020_competition/prweb17232488.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related medicine news :

1. Actuate Therapeutics Announces Initiation of Additional Clinical Studies for 9-ING-41
2. Eolas Therapeutics Announce Initiation of a Phase I Clinical Trial for AZD4041, an Orexin-1 Receptor Antagonist for Smoking Cessation
3. EMulate® Therapeutics Announces Multiple Presentations on the Voyager and Hælo® systems
4. Better Therapeutics Demonstrates Proof of Concept in the Use of Digital Biomarkers to Improve Treatment Outcomes
5. FDA Accepts for Filing the Humanitarian Device Exemption Application For EMulate Therapeutics™ Hælo™ Pediatric System
6. Neutron Therapeutics Installs Europe’s First Accelerator-Based Boron Neutron Capture Therapy (BNCT) Platform – On Track for First Cancer Patient Treatment in 2019
7. Saol Therapeutics Announces CDC has Updated Information Related to Use and Availability of VARIZIG® (Varicella Zoster Immune Globulin [Human])
8. uBiome Receives Patent for Diagnostics and Therapeutics for Endocrine System Conditions
9. uBiome Receives Patent for Diagnostics and Therapeutics for Microbiome Functional Features
10. Madam Therapeutics Closes €1.1 Million Financing Round to Develop Novel Antibiotics Against Drug Resistant Bacteria
11. Symbiomix Therapeutics Receives FDA Approval of Solosec™ (secnidazole) Oral Granules Following Four-Year Collaboration with Catalent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/5/2020)... , ... August 05, 2020 , ... ... loss of consciousness, seizures, prolonged length of hospital stay, or even death. A ... of insulin-treated patients with Type 2 diabetes to see if the use of ...
(Date:8/5/2020)... ... August 05, 2020 , ... ... industry, as president of the largest veterinarian-owned purchasing Cooperative in the United States. ... various roles where she gained extensive knowledge and experience in the animal health ...
(Date:8/5/2020)... ... August 05, 2020 , ... Today, YPO Africa , a global leadership ... platform for Africa, announced that they have entered into a unique bilateral alliance. The ... support each other in their African impact efforts, with an initial focus on YPO’s ...
(Date:8/5/2020)... ... August 04, 2020 , ... MemoryCare.com , a ... the Best Memory Care Facilities in Austin, Texas. The guide identifies 14 memory ... , According to the Alzheimer’s Association , 5.6 million people aged 65 ...
(Date:8/3/2020)... ... 2020 , ... Evolution Labs announced today that St. Lucie ... developed to help students navigate a range of issues related to Mental Health, ... provide their students with preventative lessons after recent studies of social media impact ...
Breaking Medicine News(10 mins):
(Date:7/31/2020)... CITY, Texas (PRWEB) , ... July 31, 2020 , ... ... Design Studios has been providing residents of Missouri City, TX, with a wide ... Highway 6, Suite 300, is a state-of-the-art dental facility that is not far from ...
(Date:7/31/2020)... ... July 31, 2020 , ... A June 29 article ... believed to have been caused by tiny worms that inhabited the mouths of those ... including details of small creatures that are commonly found in water supplies. Marina Del ...
(Date:7/22/2020)... ... July 22, 2020 , ... With the new school year ... attention. A new 8 page white paper, “Infectious Disease Control for Schools Using ... The Germ-Fogger™ disinfecting-fogger is uniquely well suited to the requirements of disinfecting primary ...
Breaking Medicine Technology: